Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Single Agent Abraxane as Second Line Therapy in Bladder Cancer

The recruitment status of this study is unknown because the information has not been verified recently.
Verified July 2011 by Sunnybrook Health Sciences Centre.
Recruitment status was  Recruiting
Celgene Corporation
Information provided by:
Sunnybrook Health Sciences Centre Identifier:
First received: May 21, 2008
Last updated: July 19, 2011
Last verified: July 2011
No Study Results Posted on for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: September 2011
  Primary Completion Date: January 2011 (Final data collection date for primary outcome measure)
Publications automatically indexed to this study by Identifier (NCT Number):